Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test-Reference-Cited by-同舟云学术

Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test

Published:2011-05-28 Issue:1 Volume:69 Page:125-135
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Michael M.,Cullinane C.,Hatzimihalis A.,O’Kane C.,Milner A.,Booth R.,Schlicht S.,Clarke S. J.,Francis P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-011-1676-y.pdf

Reference45 articles.

1. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155–163

2. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA (2004) Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10:1976–1983

3. Baker SD, Ten Tije AJ, Carducci MA, Gelderblom H, Dawkins FW, McGuire WP, Verweij J (2004) Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22: Abstr 2006

4. Breen KJ, Bury RW, Calder IV, Desmond PV, Peters M, Mashford ML (1984) A [14C]phenacetin breath test to measure hepatic function in man. Hepatology 4:47–52

5. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity;Frontiers in Pharmacology;2024-06-19

2. CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study;Frontiers in Pharmacology;2023-07-04

3. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis;Cancer Chemotherapy and Pharmacology;2022-01-06

4. CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?;Frontiers in Genetics;2021-07-08

5. Induced volatolomics of pathologies;Nature Reviews Chemistry;2021-02-02